Optimal Adjuvant Chemo and Targeted Therapy for Early Breast Cancer—CDK 4/6 Inhibitors: ASCO Guideline Rapid Recommendation Update

– An ASCO Reading Room selection

July 16, 2024

Rachel A. Freedman, MD, MPH, Jennifer L. Caswell-Jin, MD, Michael Hassett, MD, MPH, Mark R. Somerfield, PhD, and Sharon H. Giordano, MD, MPH, for the Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel

Journal of Clinical Oncology

This Reading Room is a collaboration between MedPage Today® and:

Below is the abstract of the article.

Read the full article PDF by clicking here

or on the link below.

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the . The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients.

In 2020, ASCO published a guideline on the selection of optimal . This is a rapid recommendation update of that guideline that addresses, in turn, the adjuvant use of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib in patients with stage II and III breast cancer.

Read an interview about the guideline update here and expert commentary about it here.

Read the full article

Optimal Adjuvant Chemo and Targeted Therapy for Early Breast Cancer—CDK 4/6 Inhibitors: ASCO Guideline Rapid Recommendation Update

Primary Source

Journal of Clinical Oncology

Source Reference:

�鶹��ýӰ��